Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
OnKure Therapeutics, Inc.
13G/A
Amendment 1
OKUR · 68277Q105
|
2.4% |
8/10/2026
Event 6/30/2026
|
|||
| Prosight Management, LP | 2.4% | ||||
| Prosight Fund, LP | 0.1% | ||||
| Prosight Plus Fund, LP | 0.5% | ||||
| Prosight Partners, LLC | 2.4% | ||||
| W. Lawrence Hawkins | 2.4% | ||||
|
MeiraGTx Holdings plc
13G/A
Amendment 3
MGTX · G59665102
|
4.0% |
2/13/2026
Event 12/31/2025
|
|||
| Prosight Management, LP | 4.0% | ||||
| Prosight Fund, LP | 0.2% | ||||
| Prosight Plus Fund, LP | 0.9% | ||||
| Prosight Partners, LLC | 4.0% | ||||
| W. Lawrence Hawkins | 4.0% | ||||
|
Adc Therapeutics SA
13G/A
Amendment 4
ADCT · H0036K147
|
6.8% |
2/13/2026
Event 12/31/2025
|
|||
| Prosight Management, LP | 6.8% | ||||
| Prosight Fund, LP | 0.3% | ||||
| Prosight Plus Fund, LP | 1.5% | ||||
| Prosight Partners, LLC | 6.8% | ||||
| W. Lawrence Hawkins | 6.8% | ||||
|
Janux Therapeutics, Inc.
13G
JANX · 47103J105
|
5.3% |
2/6/2026
Event 2/3/2026
|
|||
| Prosight Management, LP | 5.2% | ||||
| Prosight Fund, LP | 0.2% | ||||
| Prosight Plus Fund, LP | 1.1% | ||||
| Prosight Partners, LLC | 5.2% | ||||
| W. Lawrence Hawkins | 5.3% | ||||
|
OnKure Therapeutics, Inc.
13G
OKUR · 68277Q105
|
5.8% |
11/28/2025
Event 11/24/2025
|
|||
| Prosight Management, LP | 5.8% | ||||
| Prosight Fund, LP | 0.3% | ||||
| Prosight Plus Fund, LP | 1.3% | ||||
| Prosight Partners, LLC | 5.8% | ||||
| W. Lawrence Hawkins | 5.8% | ||||
|
Mural Oncology plc
13G/A
Amendment 1
MURA · G63365103
|
0% |
11/13/2025
Event 9/30/2025
|
|||
| Prosight Management, LP | 0% | ||||
| Prosight Fund, LP | 0% | ||||
| Prosight Plus Fund, LP | 0% | ||||
| Prosight Partners, LLC | 0% | ||||
| W. Lawrence Hawkins | 0% | ||||
|
ADC Therapeutics SA
13G/A
Amendment 3
ADCT · H0036K147
|
5.8% |
11/13/2025
Event 9/30/2025
|
|||
| Prosight Management, LP | 5.8% | ||||
| Prosight Fund, LP | 0.3% | ||||
| Prosight Plus Fund, LP | 1.3% | ||||
| Prosight Partners, LLC | 5.8% | ||||
| W. Lawrence Hawkins | 5.8% | ||||
|
Shattuck Labs, Inc.
13G/A
Amendment 3
STTK · 82024L103
|
9.9% |
11/13/2025
Event 9/30/2025
|
|||
| Prosight Management, LP | 9.9% | ||||
| Prosight Fund, LP | 0.9% | ||||
| Prosight Plus Fund, LP | 4.9% | ||||
| Prosight Partners, LLC | 9.9% | ||||
| W. Lawrence Hawkins | 9.9% | ||||
|
Mural Oncology plc
13G
MURA · G63365103
|
5.2% |
6/26/2025
Event 6/23/2025
|
|||
| Prosight Management, LP | 5.2% | ||||
| Prosight Fund, LP | 0.3% | ||||
| Prosight Plus Fund, LP | 1.1% | ||||
| Prosight Partners, LLC | 5.2% | ||||
| W. Lawrence Hawkins | 5.2% | ||||
|
MeiraGTx Holdings plc
13G/A
Amendment 2
MGTX · G59665102
|
5.4% |
5/14/2025
Event 3/31/2025
|
|||
| Prosight Management, LP | 5.4% | ||||
| Prosight Fund, LP | 0.3% | ||||
| Prosight Plus Fund, LP | 1.2% | ||||
| Prosight Partners, LLC | 5.4% | ||||
| W. Lawrence Hawkins | 5.4% | ||||
|
Vincerx Pharma, Inc.
13G/A
Amendment 2
VINC · 92731L304
|
4.99% |
2/12/2025
Event 12/31/2024
|
|||
| Prosight Management, LP | 4.99% | ||||
| Prosight Fund, LP | 0.4% | ||||
| Prosight Plus Fund, LP | 1.3% | ||||
| Prosight Partners, LLC | 4.99% | ||||
| W. Lawrence Hawkins | 4.99% | ||||